Blockchain Registration Transaction Record

ABVC BioPharma Anticipates $19 Million Cash Income from Global Licensing Agreements and CDMO Acquisition

ABVC BioPharma announces $19 million in cash income from global licensing agreements and CDMO acquisition, reinforcing its strategic positioning for long-term growth in psychiatric disorders, ophthalmology, and oncology.

ABVC BioPharma Anticipates $19 Million Cash Income from Global Licensing Agreements and CDMO Acquisition

This news matters as ABVC's strategic partnerships and acquisitions demonstrate its commitment to innovation and revenue growth in key therapeutic areas. The $19 million expected income underscores the company's position as a leading player in the global pharmaceutical market, with a strong revenue pipeline set to drive future expansion and value creation.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x9c08993930780a23ad89587b5e496a59223fadb9bd5219c26cd238da619ff728
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprinticyEwMS-062795b02ae0e2f3f5395b647952f209